Incidence of cerebral metastases in patients treated with trastuzumab for metastatic breast cancer by Clayton, A.J. et al.
Incidence of cerebral metastases in patients treated with
trastuzumab for metastatic breast cancer
AJ Clayton1, S Danson1, S Jolly1, WDJ Ryder1, PA Burt1, AL Stewart1, PM Wilkinson1, RS Welch1, B Magee1,
G Wilson1, A Howell1 and AM Wardley*,1
1Departments of Medical and Clinical Oncology, Christie Hospital NHS Trust, Wilmslow Road, Withington, Manchester, M20 4BX, UK
Trastuzumab is an effective treatment for patients with metastatic breast cancer (MBC) that overexpresses HER-2. A high incidence
of brain metastases (BM) has been noted in patients receiving trastuzumab. A retrospective chart review was conducted of 100
patients commencing trastuzumab for metastatic breast cancer from July 1999 to December 2002, at the Christie Hospital. Seven
patients were excluded; five patients developed central nervous system metastases prior to starting trastuzumab, and inadequate data
were available for two. Out of the remaining 93 patients, 23 (25%) have developed BM to date. In all, 46 patients have died, and of
these 18 (39%) have been diagnosed with BM prior to death. Of the 23 patients developing BM, 18 (78%) were hormone receptor
negative and 18 (78%) had visceral disease. Univariate analysis showed a significant association between the development of cerebral
disease and both hormone receptor status and the presence of visceral disease. In conclusion, a high proportion of patients with MBC
treated with trastuzumab develop symptomatic cerebral metastases. HER-2-positive breast cancer may have a predilection for the
brain, or trastuzumab therapy may change the disease pattern by prolonging survival. New strategies to address this problem require
investigation in this group of patients.
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The human epidermal growth factor receptor family (HER 1– 4) is
involved in the control of cell growth and differentiation.
Amplification of the HER-2 gene leads to overexpression of the
receptor, which has been implicated in oncogenic transformation
and tumour genesis. The HER-2 receptor dimerises with other
members of the HER family to initiate cell signalling cascades,
leading to increased cell growth and division. Transfection of the
HER-2 gene into human tumour cell lines leads to the development
of a more aggressive tumour cell phenotype (Neve et al, 2001;
Rubin and Yarden, 2001). Amplification of the HER-2 gene with
overexpression of the receptor is detected in 20–30% of breast
cancers (Slamon et al, 1987, 1989) and is associated with a worse
prognosis compared to those with HER-2-negative tumours
(Slamon et al, 1987; Emi et al, 2002). Whether HER-2 is predictive
for response to chemotherapy, and to hormonal therapy, remains
controversial (Fournier et al, 2002). There is no controversy about
the fact that HER-2 overexpression predicts the response to
trastuzumab. Trastuzumab (Herceptint) is a recombinant huma-
nised monoclonal antibody against the HER-2 receptor. Trastuzu-
mab administered either alone or in combination with cytotoxic
chemotherapy is being used increasingly in clinical practice.
Trastuzumab monotherapy is associated with response rates of
26% in the first-line setting for metastatic disease (Vogel et al,
2002), and 15% in patients previously treated with chemotherapy
(Cobleigh et al, 1999). In combination with chemotherapy,
trastuzumab therapy is associated with response rates of up to
70–80% (Seideman et al, 2001). Trastuzumab prolongs both the
response duration and survival of patients with tumours over-
expressing HER-2, when administered with chemotherapy com-
pared with chemotherapy alone (Slamon et al, 2001).
It has recently been reported that trastuzumab levels in the CSF
following intravenous infusion are 300-fold lower than serum levels,
implying that i.v. trastuzumab is unlikely to be effective against
CNS disease (Pestalozzi and Brignoli, 2000). Unfortunately, the
prognosis of patients following the development of CNS disease is
generally poor, with median survival times reported around 4–6
months. Historical data indicate that the incidence of symptomatic
brain metastases (BM) in patients with metastatic breast cancer is
around 10% (DiStefano et al, 1979; Stewart et al, 1981; Tsukada et al,
1983). However, a large post mortem study has reported the
presence of central nervous system disease in up to 29.6% of
patients dying from breast cancer (Tsukada et al, 1983). These two
observations lead inevitably to the hypothesis that the prolongation
of survival of patients with metastatic breast cancer using therapies
which do not penetrate the CNS will result in a higher incidence of
clinically overt cerebral metastases than has hitherto been observed.
A preliminary report from this institution indicated that a high
proportion of patients receiving trastuzumab therapy were
observed to develop cerebral metastases (Wardley et al, 2002).
The aim of this study was to ascertain, in a larger patient cohort,
the proportion of patients receiving trastuzumab who develop
cerebral metastases, and to explore whether any clinico-patholo-
gical correlates could be identified.
Received 2 February 2004; revised 28 April 2004; accepted 3 May 2004;
published online 20 July 2004
*Correspondence: Dr AM Wardley;
E-mail: Andrew.Wardley@christie-tr.nwest.nhs.uk
British Journal of Cancer (2004) 91, 639 – 643
& 2004 Cancer Research UK All rights reserved 0007 – 0920/04 $30.00
www.bjcancer.com
C
li
n
ic
a
l
METHODS
Using pharmacy records, all patients commencing trastuzumab at
the Christie Hospital up until the end of December 2002 were
identified. A retrospective review of the case notes extracted
information on the dates of initial diagnosis of breast cancer;
details of histology including oestrogen receptor (ER), progester-
one receptor (PR) and HER-2 status by immunohistochemistry
(CB11 antibody); each episode of disease progression; details and
dates of all therapy for breast cancer, including recording sites of
disease, and best responses to therapy in those sites. In all patients
with a diagnosis of cerebral metastases, the CNS disease
presentation was symptomatic, and was confirmed radiologically
by CT or MRI scanning.
Univariate analysis has been performed to determine the
potential influence on the time for the development of BM from
the initiation of trastuzumab therapy of the following factors: ER
status; presence of visceral (parenchymal lung or liver) metastases
at the start of trastuzumab therapy; previous neoadjuvant or
adjuvant chemotherapy; trastuzumab given with or without
chemotherapy; number of prior systemic therapies for metastatic
disease; and time from diagnosis to the development of MBC. The
primary outcome analysed was the time from the start of
trastuzumab to the development of BM. Cases that did not develop
BM were censored at their time of death or last follow-up as
appropriate. Freedom from BM curves was estimated using the
Kaplan–Meier method and univariate comparisons between
subgroups were made using the log-rank test. Plots and test
results were obtained using the S-Plus computer software. This
study was conducted in accordance with local ethical guidelines.
RESULTS
Study population
In all, 100 patients have been treated with trastuzumab for
metastatic breast cancer at the Christie hospital from October 1999
to December 2002. Two patients with inadequate follow-up
documentation and five patients diagnosed with CNS metastases
prior to the start of trastuzumab were excluded from analysis. The
characteristics of the 93 patients in the study population are shown
in Table 1.
HER-2 expression by immunohistochemistry was 3þ in 87
(94%) of the patients. In all, 41 of the patients had tumours
expressing ER, the remaining 52 were ER negative.
A total of 57% of the patients had a response of stable disease
(SD) or better on trastuzumab. Stable disease was defined as the
absence of either disease response or progression radiologically (or
clinically for chest wall disease) for at least 6 months.
The median duration of trastuzumab therapy for the group was
224 days or 32 weeks (1– 207 weeks). The median survival of this
group of patients was 2 years.
In all, 46 patients in the group had died at the time of analysis,
and the median follow-up of the patients in the group who
remained alive was 10.8 months from the start of trastuzumab.
Patients developing BM
Out of 93 patients, 23 (25%) developed symptomatic BM after
commencing trastuzumab therapy. All of the 23 patients developed
intracerebral metastases, with four having evidence of meningeal
disease in addition. Of the 46 patients who have now died from
their breast cancer, 18 (39%) were diagnosed with BM prior to
death. Of the 47 patients who remained alive, five (11%) had
developed CNS disease at the time of analysis.
The proportion of patients developing BM at 1 year from the
start of trastuzumab was estimated to be 26.1% (95% confidence
interval of 13.5–36.9%).
The median duration of trastuzumab treatment among those
patients developing BM was 293 days (42–1448). The median time
from the initiation of trastuzumab therapy to the development of
BM was 305 days (39– 933).
Following the diagnosis of BM, 16 out of 23 patients have been
treated with radiotherapy to date. Out of the 23 patients developing
BM, 16 went on to receive further systemic therapy. In all, 10
patients continued trastuzumab, six of these also received further
cytotoxic chemotherapy (three in combination with trastuzumab,
and three following trastuzumab), and four received further
trastuzumab alone. Six other patients did not continue trastuzu-
mab but received further cytotoxic chemotherapy.
The median survival of the patients from the diagnosis of
cerebral metastases was 5.4 months (Figure 1). The median
survival of those 16 patients who went on to receive further
systemic therapy was 5.6 months.
Out of the 23 patients developing CNS disease, 18 (78%) had SD
or were better in sites other than the CNS in response to
trastuzumab therapy. In all, 16 patients (70%) developed cerebral
metastases while receiving trastuzumab therapy; in 13 out of 16
(82%), the CNS was the first site of symptomatic disease
progression, and in 11 out of 16 (69%) the only site of disease
progression at that time.
Five of 41 (12%) patients with ER-positive breast cancer
developed BM compared to 18 out of 52 (35%) with ER-negative
disease. Out of 51 patients with visceral disease at the start of
trastuzumab therapy, 18 (35%) developed BM, compared with only
five of 42 (12%) patients without visceral disease at the start of
trastuzumab therapy. Univariate analysis showed a significant
association between the time to the development of BM from the
initiation of trastuzumab therapy and both hormone receptor
status, and the presence of visceral disease at the start of
trastuzumab therapy. This is demonstrated in Figures 2A–C.
Table 1 Characteristics of patients with metastatic breast cancer treated
with trastuzumab
Number in study group 93
Median age (range) 48 (23–76)
HER2 immunohistochemistry
2+ 6
3+ 87
Hormone receptor status
ER+ 41 (44%)
ER 52 (56%)
ER 47 (51%)
ER 5 (5%)
Trastuzumab given
Alone 30 (32%)
With chemotherapy 53 (57%)
With hormonal therapy 8 (9%)
With chemotherapy and hormonal therapy 2 (2%)
Line of therapy for trastuzumab
First systemic therapy 44 (47%)
Second systemic therapy 31 (33%)
Third line systemic therapy 18 (19%)
Disease distribution at the start of trastuzumab therapy
Visceral 51 (55%)
Nonvisceral 42 (45%)
Response to trastuzumab
Stable disease or better 53 (57%)
PD 33 (35%)
Not assessed/not assessable 7 (8%)
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There was no association between development of BM and other
factors analysed (i.e. neoadjuvant or adjuvant chemotherapy;
whether trastuzumab was given alone or with chemotherapy; the
number of prior systemic therapies for metastatic disease; or the
time from initial presentation to the development of metastatic
disease).
DISCUSSION
A high proportion, 23 out of 93 (25%), of this cohort of patients
with metastatic breast cancer treated with trastuzumab at a single
institution, have developed symptomatic BM. Out of the 46
patients who have died, 18 (39%) have developed symptomatic
cerebral metastases pre-mortem. The 95% confidence interval for
the incidence of BM after 1 year of trastuzumab in this study is
13.5– 36.9%, the lower limit of which is higher than the expected
incidence of CNS metastases pre-mortem in historical series. The
large study from Tsukada reports 1044 post mortems of breast
cancer patients, with CNS disease present in 309 (29.6%), of which
only 96 cases were diagnosed clinically prior to death (9%)
(Tsukada et al, 1983).
There are other reports in the literature of a high incidence
of CNS disease in patients with metastatic breast cancer
treated with trastuzumab. The Dana Faber Partners Cancer Care
reported CNS disease in 34% of 122 patients with metastatic breast
cancer overexpressing HER-2 treated with trastuzumab (Bendell
et al, 2003). Heinrich et al (2003) reported cerebral metastases in
43% of 51 patients with HER-2-overexpressing breast cancer
receiving trastuzumab. Brufsky et al (2003), in a phase II study of
docetaxel, carboplatin, and trastuzumab in 38 patients, observed
that out of those patients progressing on therapy 50% developed
CNS disease.
The rate of BM is particularly high in patients deriving systemic
benefit from trastuzumab: 18 out of 23 (78%) patients who
developed BM had SD or were better in response to trastuzumab.
In the German series, 79% of the 22 patients who developed CNS
disease did so while responding systemically to trastuzumab
(Heinrich et al, 2003). In the American series, 15 of the 21 patients
(71%) treated with trastuzumab as first-line therapy developed
CNS metastases while still responding or having achieved SD on
trastuzumab (Bendell et al, 2003).
The development of BM in our series was found to be
significantly associated with ER negativity, and with the presence
of visceral metastases at the start of trastuzumab therapy. In
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Figure 1 Survival of patients following diagnosis of BM.
0
Years from starting trastuzmab
0
20
40
60
80
100
%
 fr
ee
 fr
om
 b
ra
in
 m
et
as
ta
se
s
P =0.046, log-rank test
52 41 15 12 8 3 1
41 30 15 8
ER+ (5/41)
ER- (18/52)
3 2 0
1 2 3
0 1 2 3
Years from starting trastuzmab
0
20
40
60
80
100B
C
%
 fr
ee
 fr
om
 b
ra
in
 m
et
as
ta
se
s
P =0.004, log-rank test
42 36 21 13 5 0
51 35 9
No visceral disease (5/42)
Visceral disease  (18/51)
7
1
6 4 1
0 1 2 3
Years from starting trastuzmab
0
20
40
60
80
100
%
 fr
ee
 fr
om
 b
ra
in
 m
et
as
ta
se
s
P =0.006, log-rank test
24 22 10 8 4 0 0
18 14 11 5 1 1 0
28 19 5 4 4 3 1
23 16 4 3 2 1 0
ER+ and no visceral disease (0/18)
ER− and no visceral disease (5/24)
ER− and visceral disease (13/28)
ER+ and visceral disease (5/23)
A
Figure 2 (A) Freedom from BM by ER status. (B) Freedom from BM by
the presence or not of visceral metastases at the start of trastuzumab
therapy. (C) Freedom from BM by ER status and the presence of visceral
metastases at the start of trastuzumab therapy.
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keeping with this, Bendell et al (2003) found that of patients with
CNS metastases, fewer (33 vs 64%) had received prior hormonal
therapy (a surrogate for steroid hormone receptor status), and
there was a nonsignificant preponderance of visceral disease in
patients who developed CNS disease. Others have also observed
that patients with ER-negative disease are more likely to develop
BM in comparison with patients having ER-positive tumours
(Stewart et al, 1981; Clark et al, 1987; Maki and Grossman, 2000).
There are two possible nonexclusive explanations for the
increased incidence of symptomatic CNS disease in patients
treated with trastuzumab.
Firstly, trastuzumab therapy controls systemic disease and
prolongs survival (Slamon et al, 2001), but does not cross the
blood–brain barrier (BBB), making the CNS a ‘sanctuary site’,
allowing the development of symptomatic BM which otherwise
would have remained clinically silent prior to death. It has been
shown that systemic administration of trastuzumab does not yield
significant levels in the cerebrospinal fluid (Pestalozzi and
Brignoli, 2000). There is, however, debate over whether the BBB
is meaningful in cerebral metastases, and there is evidence that
other agents which do not normally traverse the BBB may
penetrate CNS tumour deposits (Rosner et al, 1986). There is only
one report in the literature of a response to trastuzumab of CNS
disease, and this was confounded by the use of other treatment
modalities (Baculi et al, 2001).
Secondly, it is possible that tumours overexpressing HER-2 may
have a predilection for CNS. In support of this theory, in a phase II
study of docetaxel/epirubicin reporting a high incidence of CNS
disease, it was found, retrospectively, that a majority of patients
developing CNS disease had tumours overexpressing HER-2
(Crivellari et al, 2001). In addition, Miller et al (2003) found
HER-2 overexpression to be predictive of the detection of occult
CNS metastases in patients with metastatic breast cancer being
screened for clinical trial entry.
Irrespective of the reason for the observed increased incidence
of BM, the practical problem is that of the development of CNS
disease in patients with HER-2-overexpressing tumours otherwise
responding systemically to trastuzumab. Survival with BM is
generally short, of the order of 4–6 months, and could potentially
be prolonged if CNS disease could be controlled, or prevented.
Given the association with ER-negative disease, it may be possible
to further define a population within the group of patients being
treated with trastuzumab who are at particularly high risk (i.e.
those with ER-negative disease, and visceral metastases), although
this requires verification in other studies.
There could be two approaches to this problem, both of which
could potentially form the basis of a clinical trial, and there seems
to be sufficient evidence in the literature to justify such a trial. One
approach could be that of active prevention, with a trial of
prophylactic cranial irradiation (PCI) vs no CNS-directed therapy
for patients responding to trastuzumab therapy. Prolonged
survival is seen in small-cell lung cancer (SCLC) with PCI after
complete response to chemotherapy. PCI is also finding a role in
non-small-cell lung cancer (NSCLC) as new treatments improve
survival and reveal a higher incidence of BM (Pottgen and
Stuschke, 2001), which is analogous to the prolonged survival with
trastuzumab in patients with breast cancer.
An alternative approach may be one of active surveillance in
patients responding to trastuzumab. It is, of course, unknown
whether the early detection and treatment of CNS disease in this
setting would be beneficial in terms of either survival or
symptoms. With the advent of more aggressive approaches to
the treatment of limited CNS disease with surgery, and radio-
surgery, it is possible that this, in the context of controlled
systemic disease, may be beneficial (Gerosa et al, 2002). Again,
any such CNS ‘surveillance’ should be as part of a randomised
clinical trial against no surveillance, which is currently the
standard of care.
CONCLUSIONS
Among a population of patients treated with trastuzumab, a high
proportion of patients have been observed to develop BM. There
may be two factors involved:
Firstly, longer survival of patients receiving trastuzumab (which
does not cross the blood brain barrier) may allow the development
of symptomatic BM, which otherwise would have remained
clinically silent. Secondly, tumours overexpressing HER-2 may
have a predilection for the CNS.
Trials of specific CNS therapy (e.g. PCI) or surveillance should
be considered for these patients
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